Bruker (NASDAQ:BRKR) Stock Price Expected to Rise, Leerink Partners Analyst Says

Bruker (NASDAQ:BRKR) had its target price boosted by Leerink Partners from $80.00 to $85.00 in a report released on Thursday, Benzinga reports. The brokerage presently has an “outperform” rating on the medical research company’s stock. Leerink Partners‘s price target points to a potential upside of 46.40% from the stock’s current price.

A number of other research analysts have also recently commented on BRKR. Zacks Research cut shares of Bruker from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, September 2nd. Barclays lifted their price target on shares of Bruker from $58.00 to $70.00 and gave the company an “overweight” rating in a research report on Wednesday, October 7th. Citigroup reduced their price target on shares of Bruker from $60.00 to $53.00 and set a “hold” rating on the stock in a research note on Wednesday, August 5th. Stifel Nicolaus set a $50.00 price objective on shares of Bruker in a report on Wednesday, August 5th. Finally, TD Cowen upped their price objective on shares of Bruker from $60.00 to $62.00 and gave the stock a “hold” rating in a report on Tuesday, October 13th. Two investment analysts have rated the stock with a Strong Buy rating, five have given a Buy rating, six have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $59.79.

Bruker Trading Down 9.0%

NASDAQ:BRKR traded down $5.73 on Thursday, reaching $58.06. The company’s stock had a trading volume of 3,223,548 shares, compared to its average volume of 2,379,493. Bruker has a 12-month low of $32.37 and a 12-month high of $68.98. The stock has a 50 day moving average price of $58.95 and a 200 day moving average price of $50.48. The firm has a market cap of $8.85 billion, a price-to-earnings ratio of -82.94, a price-to-earnings-growth ratio of 1.73 and a beta of 1.26. The company has a quick ratio of 0.92, a current ratio of 1.85 and a debt-to-equity ratio of 0.76.

Bruker (NASDAQ:BRKR) last released its quarterly earnings results on Wednesday, November 4th. The medical research company reported $0.56 earnings per share for the quarter, topping analysts’ consensus estimates of $0.42 by $0.14. The business had revenue of $874.00 million during the quarter, compared to analysts’ expectations of $865.16 million. Bruker had a positive return on equity of 12.47% and a negative net margin of 2.35%. The company’s revenue was up 1.6% compared to the same quarter last year. During the same period in the prior year, the business posted $0.45 EPS. On average, equities analysts anticipate that Bruker will post 2.12 EPS for the current fiscal year.

Insider Buying and Selling

In other Bruker news, VP Mark Munch sold 2,000 shares of Bruker stock in a transaction dated Tuesday, September 15th. The stock was sold at an average price of $52.87, for a total value of $105,740.00. Following the completion of the transaction, the vice president directly owned 134,806 shares of the company’s stock, valued at $7,127,193.22. The trade was a 1.46% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. 27.20% of the stock is owned by company insiders.

Institutional Trading of Bruker

A number of institutional investors and hedge funds have recently bought and sold shares of BRKR. AlphaCore Capital LLC acquired a new stake in shares of Bruker during the third quarter worth about $410,000. Allspring Global Investments Holdings LLC grew its holdings in shares of Bruker by 5.6% in the third quarter. Allspring Global Investments Holdings LLC now owns 169,766 shares of the medical research company’s stock valued at $10,515,000 after purchasing an additional 8,938 shares in the last quarter. Brighton Jones LLC grew its holdings in shares of Bruker by 11.2% in the third quarter. Brighton Jones LLC now owns 12,436 shares of the medical research company’s stock valued at $805,000 after purchasing an additional 1,248 shares in the last quarter. Candriam S.C.A. grew its holdings in shares of Bruker by 0.9% in the third quarter. Candriam S.C.A. now owns 415,327 shares of the medical research company’s stock valued at $26,991,000 after purchasing an additional 3,627 shares in the last quarter. Finally, Kestra Advisory Services LLC increased its stake in Bruker by 6.0% during the 3rd quarter. Kestra Advisory Services LLC now owns 4,947 shares of the medical research company’s stock worth $320,000 after buying an additional 282 shares during the period. 79.52% of the stock is currently owned by hedge funds and other institutional investors.

More Bruker News

Here are the key news stories impacting Bruker this week:

• Positive Sentiment: Bruker reported Q3 adjusted earnings of $0.56 per share, above the $0.42 consensus, and revenue of $874 million versus estimates of about $865 million. Revenue rose 1.6% year over year. Bruker Q3 Earnings and Revenues Surpass Estimates
• Positive Sentiment: Management highlighted margin expansion and strong bookings, and said U.S. academic demand returned in Q3. The company also sees potential for double-digit EPS growth in fiscal 2027, although that outlook is forward-looking. Bruker Q3 2026 Earnings Call Highlights
• Neutral Sentiment: Bruker forecast 2026 revenue of $3.52 billion to $3.56 billion, compared with a FactSet estimate of $3.56 billion. Its adjusted EPS range of $2.10 to $2.15 broadly brackets the $2.12 estimate. Bruker 2026 Revenue Outlook
• Negative Sentiment: The outlook offered little upside to expectations, while coverage also flagged a steep goodwill charge that weighed on reported results. These concerns may have overshadowed the quarterly beat and contributed to the weaker share performance. Bruker Q3 2026: Margin Surge Masks a Steep Goodwill Charge

About Bruker

Bruker Corporation develops and manufactures scientific instruments, analytical systems and related software used to study materials, molecules and biological processes. Its technologies support research, discovery and quality control in fields including life sciences, pharmaceutical development, chemical analysis, materials science, environmental testing and clinical research.

The company’s product portfolio includes nuclear magnetic resonance and electron paramagnetic resonance systems, mass spectrometers, infrared and Raman spectroscopy instruments, X-ray analysis equipment, microscopy and nanoanalysis systems, and preclinical imaging technologies.